| GM |
Report |
EBIT-Adjusted (Q2 2026) |
BEAT |
pred ~$4.1B vs. cons $3.589B (Visible Alpha, Jul 17, 2026) |
HIGH |
| GM |
Report |
Adj. EPS Diluted (Q2 2026) |
BEAT |
pred ~$3.75 vs. cons $3.20 (Visible Alpha, Jul 17, 2026) |
HIGH |
| GM |
Report |
NA EBIT-Adjusted (Q2 2026) |
BEAT |
pred ~$3.7B vs. cons $3.231B (Visible Alpha, Jul 17, 2026) |
MEDIUM |
| GM |
Guide |
EBIT-Adjusted FY 2026 (midpoint) |
BETTER |
guide ~$14.75B vs. cons $14.714B (Visible Alpha, Jul 17, 2026) |
MEDIUM |
| GM |
Guide |
Adj. EPS FY 2026 (midpoint) |
LOWER |
guide ~$12.75 vs. cons $12.863 (Visible Alpha, Jul 17, 2026) |
MEDIUM |
| GM |
Guide |
Adj. Auto FCF FY 2026 |
BETTER |
guide maintained $9-11B vs. cons $8.494B (Visible Alpha, Jul 17, 2026) |
HIGH |
| GM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| GM |
Return |
5-day cumulative residual |
+1.0% (FADE) |
FADE - beat absorbed day-1; EPS guide midpoint below consensus pulls estimates flat-to-down; stock stabilizes above pre-print levels |
MEDIUM |